Genmab A/S

https://www.genmab.com/

Genmab A/S is a Danish international biotechnology company specializing in the discovery, creation, and development of differentiated antibody therapeutics for the treatment of cancer and other serious diseases. Headquartered in Copenhagen, Denmark, the company's mission is to improve the lives of patients through innovative antibody-based products, driven by its core purpose of "Antibody Science to Impact."

Genmab's portfolio includes eight approved antibodies utilized in various marketed products. Key offerings include EPKINLY/TEPKINLY (epcoritamab) for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma, and Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer. A significant product, DARZALEX (daratumumab), co-developed with Johnson & Johnson, is a standard of care for multiple myeloma. The company leverages proprietary technologies such as DuoBody, HexaBody, DuoHexaBody, and HexElect to develop next-generation therapeutic antibodies.

Under the leadership of President and CEO Jan Van de Winkel, Genmab has recently made strategic moves to strengthen its market position. Notable developments include the mid-2024 acquisition of ProfoundBio for $1.8 billion, which expanded its antibody-drug conjugate capabilities, and the planned acquisition of Merus N.V. for approximately $8 billion, announced in September 2025. In January 2026, Genmab partnered with Anthropic to integrate AI solutions into its research and development processes. The company also reported strong first-quarter DARZALEX sales near $4 billion in April 2026, underscoring its continued growth and focus on high-impact late-stage programs.

Latest updates

Genmab Royalty Revenue Surges to $3.96 Billion on Darzalex Sales

Event summary

  • Genmab received USD 3,964 million in royalties for the first quarter of 2026, derived from worldwide net sales of daratumumab (DARZALEX).
  • U.S. sales accounted for USD 2,208 million, while international sales totaled USD 1,756 million.
  • Royalties are paid by Johnson & Johnson (Janssen Biotech) under an exclusive worldwide license.
  • DARZALEX includes both intravenous and subcutaneous (DARZALEX FASPRO®) formulations.

The big picture

The $3.96 billion in royalties represents a significant revenue stream for Genmab, highlighting the value of its antibody technology platform and its strategic partnership with Johnson & Johnson. This demonstrates the increasing importance of royalty-based business models in the biotechnology sector, where smaller companies can leverage their intellectual property to generate substantial income without shouldering the full burden of commercialization. However, Genmab's valuation remains intrinsically tied to the continued success and sales of DARZALEX, creating a concentration risk.

What we're watching

Market Saturation
The continued high sales figures for DARZALEX suggest limited market saturation currently, but the long-term sustainability of these numbers will depend on competitive pressures and expansion into new indications.
License Terms
Future royalty rates and terms of the agreement with Johnson & Johnson will be critical to Genmab’s financial performance, and any renegotiations could significantly impact revenue.
Pipeline Risk
Genmab’s reliance on DARZALEX royalties makes its future success heavily dependent on the success of its own pipeline, and any setbacks in clinical trials could negatively impact investor sentiment.

Genmab ADC Shows Tolerability in Ovarian Cancer Combo Trial

Event summary

  • Phase 1/2 RAINFOL™-01 data indicates a tolerable safety profile for the combination of rinatabart sesutecan (Rina-S®) and bevacizumab in advanced ovarian cancer patients.
  • The ongoing Phase 3 RAINFOL-04 trial will evaluate the combination in patients with recurrent platinum-sensitive ovarian cancer (PSOC).
  • 40 patients received the combination therapy, with the most common adverse events including nausea (80%), fatigue (67.5%), anemia (55%), and neutropenia (45%).
  • No new or unexpected safety signals were observed, and no fatal adverse events were reported.

The big picture

Ovarian cancer remains a challenging therapeutic area with a high mortality rate and limited treatment options. The combination of Rina-S and bevacizumab represents a potential advancement by targeting FRα and inhibiting angiogenesis, respectively. Success in the Phase 3 trial could position Genmab to capture a significant portion of the global ovarian cancer market, estimated to be worth billions annually.

What we're watching

Clinical Trial Success
The success of the Phase 3 RAINFOL-04 trial will be critical in determining whether this combination therapy becomes a standard treatment option for PSOC, significantly impacting Genmab's future revenue projections.
Regulatory Approval
The FDA and EMA will scrutinize the RAINFOL-04 data, and the approval pathway will depend on the strength of efficacy data alongside the established safety profile.
Competitive Landscape
Given the ongoing development of other ovarian cancer therapies, Genmab must demonstrate a clear clinical advantage for Rina-S in combination to secure market share and avoid pricing pressures.

Genmab Share Buyback Signals Capital Return Amidst Profit Surge

Event summary

  • Genmab A/S held its Annual General Meeting on March 19, 2026, approving the 2025 Annual Report.
  • The company reported a profit of USD 963 million for 2025, which will be carried forward to retained earnings.
  • Six members of the Board of Directors were re-elected for a one-year term.
  • Shareholders approved a DKK 1.9 million reduction in share capital through the cancellation of treasury shares.
  • A proposal regarding Board remuneration was withdrawn and will be presented later.

The big picture

Genmab's substantial 2025 profit, coupled with the share buyback, reflects a period of strong financial performance. The decision to reduce share capital, rather than reinvesting in growth, suggests a more conservative capital allocation strategy. This move could be influenced by the current macroeconomic environment and investor expectations for consistent returns.

What we're watching

Capital Allocation
The share capital reduction suggests Genmab is prioritizing returning capital to shareholders, potentially signaling a lack of immediate M&A targets or significant internal investment opportunities.
Governance Dynamics
The withdrawal of the Board remuneration proposal warrants monitoring; it could indicate internal disagreements or a strategic shift in compensation practices.
Pipeline Execution
The company’s ability to advance its late-stage clinical pipeline will be crucial to justifying the current valuation and sustaining investor confidence.

Genmab Repurchases Shares to Offset Restricted Stock Units

Event summary

  • Genmab initiated a share buy-back program on February 17, 2026, to repurchase up to 342,130 shares with a maximum value of DKK 725 million.
  • As of March 6, 2026, the company has repurchased 249,000 shares for a total value of DKK 452.6 million.
  • Genmab holds 2,766,533 shares as treasury shares, representing 4.31% of total share capital.
  • A prior announcement incorrectly stated the accumulated shares repurchased; the corrected figure is 148,000 as of March 2, 2026.

The big picture

Genmab's share buy-back program, while relatively modest in scale (DKK 725 million), highlights a growing trend among European biotech firms utilizing share repurchases to manage executive compensation and potentially support share price. The program's connection to Restricted Stock Units underscores the increasing focus on aligning executive incentives with shareholder value, particularly as regulatory scrutiny of compensation practices intensifies.

What we're watching

Compensation Structure
The reliance on a share buy-back program to fulfill Restricted Stock Unit obligations suggests a potential misalignment of interests or a lack of alternative compensation strategies, which could draw scrutiny from governance bodies.
Shareholder Perception
The market's reaction to the buy-back program will reveal whether investors view it as a positive signal of undervaluation or a necessary expense tied to executive compensation.
Program Completion
The speed at which Genmab completes the buy-back program, scheduled to conclude by March 31, 2026, will indicate the company’s commitment and ability to execute its stated intentions.

Genmab to Present at Key Healthcare Investor Conferences

Event summary

  • Genmab executives will participate in three investor conferences in March 2026.
  • Presentations will occur at the TD Cowen Healthcare Conference (March 3), Leerink Healthcare Conference (March 10), and Barclays Global Healthcare Conference (March 11).
  • Webcasts of the presentations will be available on Genmab’s investor relations website.
  • The conferences are located in Boston, Miami, and Miami respectively.

The big picture

Genmab’s participation in these conferences signals a proactive effort to engage with investors and manage expectations amidst a competitive landscape for antibody therapeutics. These events provide a platform for Genmab to reinforce its strategic narrative and address any emerging concerns. The choice of conferences—TD Cowen, Leerink, and Barclays—suggests a targeted approach to reach key institutional investors.

What we're watching

Conference Content
The specific topics and messaging during the fireside chats will reveal management’s priorities and outlook for the coming year, particularly regarding pipeline progress and commercialization strategies.
Analyst Scrutiny
The questions posed by analysts at these conferences will highlight key areas of investor concern, potentially exposing vulnerabilities in Genmab’s valuation or strategic direction.
Webcast Engagement
The level of engagement and questions during the webcasts will indicate the broader investor community’s interest and scrutiny of Genmab’s performance and future prospects.

Genmab's 2025 Gains Driven by Darzalex Royalties, Merus Acquisition

Event summary

  • Genmab’s 2025 revenue reached $3.72 billion, a 19% increase driven by royalties and product sales.
  • The acquisition of Merus N.V. added petosemtamab, a late-stage therapy asset, to Genmab’s pipeline.
  • DARZALEX royalties accounted for approximately $2.7 billion of Genmab’s 2025 revenue.
  • EPKINLY/TEPKINLY net sales grew to $468 million in 2025, up 67% year-over-year.
  • Genmab anticipates 2026 revenue between $4.1 and $4.4 billion, with operating expenses expected to rise to $2.7–$2.9 billion.

The big picture

Genmab's strong performance in 2025 highlights the benefits of its royalty-based business model, but also underscores the need to balance this with internal product development and acquisitions. The Merus acquisition, valued at approximately $700 million, signals a strategic shift towards greater ownership of pipeline assets and reduces reliance on partnerships. The company's growth trajectory will be closely tied to the continued success of J&J’s DARZALEX franchise and the successful advancement of its own late-stage programs.

What we're watching

Royalty Dependence
Genmab's substantial reliance on DARZALEX royalties creates vulnerability to changes in J&J’s sales performance and potential royalty rate adjustments, necessitating diversification of revenue streams.
Integration Risk
The successful integration of Merus N.V. and its petosemtamab asset will be critical to realizing the anticipated transformational opportunity, requiring careful management of resources and potential synergies.
Execution Risk
Genmab’s ambitious 2026 revenue guidance hinges on continued strong performance of existing products and successful execution of late-stage development programs, exposing the company to potential setbacks.

Genmab Royalty Revenue Surges to $14.4 Billion on Darzalex Sales

Event summary

  • DARZALEX® (daratumumab) net sales reached USD 14.351 billion in 2025.
  • U.S. sales accounted for USD 8.266 billion, while international sales totaled USD 6.085 billion.
  • Genmab receives royalties on worldwide net sales under an exclusive license agreement with Johnson & Johnson.
  • DARZALEX FASPRO®, the subcutaneous formulation, contributed to the overall sales figure.

The big picture

Genmab’s substantial royalty revenue from DARZALEX highlights the lucrative nature of licensing agreements in the biotechnology sector. The $14.4 billion in sales underscores the drug’s significant market penetration in multiple myeloma treatment, but also creates a dependency that Genmab must actively mitigate through internal drug development. The company's future success hinges on its ability to generate new revenue streams beyond this single product.

What we're watching

Competition
The emergence of biosimilars for DARZALEX will likely erode sales and royalty income for Genmab, requiring a focus on pipeline innovation to offset potential losses.
Contractual Risk
Future royalty rates are subject to renegotiation with Johnson & Johnson, and any changes could significantly impact Genmab’s financial performance.
Pipeline Progress
Genmab’s ability to advance its pipeline of antibody-based therapeutics will be crucial for long-term growth and diversification beyond DARZALEX royalties.

Genmab's Epcoritamab Shows PFS Benefit in DLBCL Trial, OS Falls Short

Event summary

  • Genmab announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (EPKINLY®/TEPKINLY®) as monotherapy.
  • The trial demonstrated a statistically significant improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.74 (95% CI: 0.60-0.92).
  • Overall survival (OS) showed a HR of 0.96 (95% CI: 0.77-1.20), failing to reach statistical significance.
  • The study enrolled 483 patients with relapsed/refractory DLBCL ineligible for HDT-ASCT, comparing epcoritamab to standard chemotherapy regimens (R-GemOx, BR).

The big picture

The EPCORE DLBCL-1 results represent a significant step forward for bispecific antibody therapies in DLBCL, a market with approximately 25,000 new cases annually in the U.S. While the PFS benefit is encouraging, the lack of OS significance introduces uncertainty. Genmab and AbbVie's collaboration faces the challenge of demonstrating a comprehensive benefit profile to secure broad adoption and maximize the commercial potential of epcoritamab, especially given the competitive landscape of existing therapies.

What we're watching

Regulatory Approval
The engagement with regulatory authorities will be critical; the lack of statistical significance in OS could influence the speed and scope of potential approvals.
Clinical Trial Data
The full trial results, including detailed subgroup analyses, will reveal the impact of factors like the pandemic and newer therapies on the observed outcomes.
Pipeline Progression
The success of the EPCORE DLBCL-2 and EPCORE DLBCL-4 trials, particularly the combination with R-CHOP, will be key to establishing epcoritamab’s broader role in DLBCL treatment.

Genmab Integrates Anthropic's AI for Accelerated Drug Development

Event summary

  • Genmab A/S has partnered with Anthropic to integrate agentic AI solutions powered by Claude into its research and development processes.
  • The collaboration aims to accelerate data processing, analysis, and document generation within Genmab’s clinical development programs.
  • Genmab’s Chief Medical Officer, Tahamtan Ahmadi, stated the partnership will reduce manual burden and allow scientists to focus on strategic work.
  • Anthropic’s Kate Jensen emphasized the focus on patient outcomes and getting therapies to market faster.

The big picture

Genmab’s partnership with Anthropic reflects a broader trend of biopharmaceutical companies leveraging generative AI to improve R&D efficiency and accelerate drug discovery. While AI offers the potential to significantly reduce development timelines and costs, the successful implementation of these technologies requires careful planning, robust data governance, and a commitment to maintaining human oversight. This move positions Genmab to compete more effectively in a market increasingly driven by data and digital innovation.

What we're watching

Execution Risk
The success of this partnership hinges on Genmab’s ability to effectively integrate Anthropic’s AI solutions into its existing workflows and ensure human oversight remains robust.
Competitive Landscape
Other biotech firms will likely follow Genmab’s lead, intensifying competition for AI talent and potentially driving up the cost of similar partnerships.
Regulatory Scrutiny
As AI becomes more prevalent in drug development, regulatory bodies will likely increase scrutiny of AI-driven processes and data integrity, potentially impacting Genmab’s timelines.

Genmab to Present at J.P. Morgan Healthcare Conference

Event summary

  • Genmab CEO Jan van de Winkel will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 (PST) / January 14, 2026 (CET).
  • The presentation will be webcast live and archived on Genmab’s website.
  • Genmab is a biotechnology company with eight approved antibody medicines and a late-stage clinical pipeline.
  • The company is headquartered in Copenhagen, Denmark, with international operations.

The big picture

Genmab's participation in the J.P. Morgan Healthcare Conference signals a continued effort to engage with key investors and analysts. The conference itself is a bellwether for the biotech sector, and Genmab's presence underscores its ambition to remain a significant player in the antibody therapeutics space, a market increasingly driven by complex and expensive therapies.

What we're watching

Pipeline Progress
The conference presentation will likely focus on the progress of Genmab’s late-stage clinical pipeline, and investor sentiment will hinge on any updates regarding timelines or trial results for key programs.
Competitive Landscape
Given the crowded antibody therapeutics market, Genmab’s ability to differentiate its offerings and maintain a competitive edge will be under scrutiny, particularly as larger pharmaceutical companies increase investment in similar modalities.
Financial Outlook
The presentation will provide insight into Genmab’s financial outlook, and the market will assess whether the company can sustain its growth trajectory amidst potential regulatory hurdles and manufacturing challenges.
CID: 410